Study shows how normal cells influence tumor growth

October 21, 2009

COLUMBUS, Ohio - It was once thought that the two communities of cells within a cancerous breast tumor - fast-growing malignant cells and the normal cells that surround them - existed independently, without interaction. Then evidence emerged indicating that the normal-looking cells encouraged cells within the tumor to become malignant, but how the one community influenced the other wasn't known.

A new study led by Ohio State University cancer researchers published in the Oct. 22 issue of Nature has begun solving the mystery. It shows for the first time that the loss of a gene called PTEN from one type of those surrounding cells can dramatically alter the tumor environment in ways that foster tumor growth.

"Our findings reveal a new role for this gene in the tumor environment, which could lead to entirely new treatments for breast cancer and perhaps other solid tumors using agents that target cells surrounding the tumor, as well as the cancer cells themselves," says co-principal investigator Gustavo Leone, associate professor of molecular virology, immunology and medical genetics at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The findings should also improve the understanding of breast cancer and of other conditions that are influenced by the local tissue environment such as autoimmune disease, lung fibrosis and neurodegenerative diseases.

The PTEN gene produces a protein that is a key regulator of cell metabolism, and it is lost in many human cancers.

This new study shows that when PTEN is lost in fibroblasts, a principle cell component of the tissue that surrounds a tumor, it dramatically alters the structure and biochemical make-up of the tumor environment. For example, levels of the fibrous protein collagen rise, inflammatory cells called macrophages migrate into the tumor and the number of tumor blood vessels increases. These events all favor tumor growth.

"Our study demonstrates that PTEN in surrounding fibroblasts plays an important role in suppressing cancer development," says co-principal investigator Michael Ostrowski, professor and chair of molecular and cellular biochemistry and co-director of the cancer center's Molecular Biology and Cancer Genetics Program.

To show this, Leone, Ostrowski and their colleagues removed PTEN from fibroblasts in the mammary glands of mice. They were surprised to discover that PTEN regulates a second gene, called Ets2, which executes the changes that occur in the tumor environment when PTEN is lost.

"Remarkably, this animal model mimics many of the features observed in human breast cancer, " Leone says, "so it should help us evaluate experimental agents that might be used in combination therapies that target faulty cells in the tumor environment, as well as cancer cells."
-end-
Funding from the National Cancer Institute, the Komen Breast Cancer Foundation, the Evelyn Simmers Charitable Trust, a Terry Fox New Frontiers Group Grant, and the Natural Science and Engineering Research Council of Canada Discovery Grants Program supported this research. Leone is the recipient of the Pew Charitable Trusts Scholar Award and the Leukemia and Lymphoma Society Scholar Award.

Ohio State University Wexner Medical Center

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.